Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Merck KGaA Q2 Profit Surges 3.2% as Pipeline & Market Access Strengthen Growth

Merck KGaA sees modest Q2 profit growth, beating forecasts with a €2.1 bn operating profit and a strong pharma pipeline, while navigating patent cliffs and M&A opportunities.

Lisa Martinez

08/08/2026, 22:01

4 minutes to read

Pfizer’s First‑Half Results Show Strong Earnings, Pipeline Growth and Strategic Patent‑Cliff Resilience

Pfizer’s first‑half earnings show strong revenue, high‑margin launches and a resilient pipeline that mitigates patent cliffs, positioning the pharma giant for growth and strategic M&A.

Lisa Martinez

08/08/2026, 20:51

4 minutes to read

Genmab Surges in Q2: 25% Revenue Growth, Strong Royalty Upswing, & Elevated Full‑Year Outlook

Genmab’s Q2 earnings exceed expectations, driven by Darzalex royalties and rising Epkinly sales, prompting higher full‑year guidance and a strong pipeline outlook.

Lisa Martinez

07/08/2026, 18:18

4 minutes to read

Merck KGaA Q2 Beats Estimates, Raises 2026 Guidance to €21 B, Driving Growth in Rare‑Disease & Lab Tech

Merck KGaA’s Q2 beats estimates, boosting 2026 outlook. Discover how its rare‑disease drugs, lab tech and strategic M&A are driving high‑margin growth and investor confidence.

Lisa Martinez

07/08/2026, 11:46

4 minutes to read

Pfizer Q2 2026: $17.6B Revenue, $2.4B Net Income & Oncology‑Obesity Growth Surge

Pfizer’s Q2 2026 earnings reveal a 12.3% revenue lift and $2.4B net profit, driven by oncology and obesity wins, strong market‑access contracts, and a focused M&A strategy to sustain growth.

Lisa Martinez

06/08/2026, 21:26

4 minutes to read

Novo Nordisk Q2 Results: Strong Profit, GLP‑1 Resilience & Future Growth Strategy

New‑Nordisk Q2 highlights solid margins, GLP‑1 dominance & patent‑cliff strategy—outperforming competitors while safeguarding pricing and IP in a tough market.

Lisa Martinez

06/08/2026, 20:56

4 minutes to read

Danaher Drives Growth: CEO Change, Phantom Shares, & Diagnostics Expansion

Danaher’s new CEO, Julie Montgomery, leads a strategic shift with director‑level phantom share incentives and key acquisitions, boosting diagnostics growth and shareholder value.

Lisa Martinez

05/08/2026, 19:51

4 minutes to read

Biogen Upside: Analyst Upgrades, Strong Pipeline, & Patent‑Cliff Strategy Drive Growth

Biogen’s analyst upgrades, strong pipeline, and market‑access focus signal solid growth prospects amid upcoming patent cliffs, boosting investor confidence.

Lisa Martinez

05/08/2026, 12:43

4 minutes to read

How AstraZeneca’s BMS Merger Speculation and Share‑Issuance Affects Market Access

How a possible AstraZeneca‑BMS merger could reshape market access, innovation, and share pricing – dive into the numbers, risks, and upside of this £400 bn pharma deal.

Lisa Martinez

04/08/2026, 19:55

4 minutes to read

Haleon’s 2026 Q2 Update: ₹2,000‑Crore India Factory, Low‑Price Packs, and a 12% Oral‑Health Surge

Haleon PLC boosts India presence: ₹2,000 cr local plant, low‑price oral‑health packs, and a 12% revenue lift, aiming to capture 15% market share.

Lisa Martinez

03/08/2026, 17:35

4 minutes to read

Newer articles Older articles